

# ATTACHMENT 1: SUPPLEMENTARY TABLES

**ANNUAL REPORT 2024**

PCOR-ANZ 2020-2022

Patterns of care and patient-reported outcomes.



1 Population characteristics

**Table S1: Number of registrants per Jurisdiction, per diagnosis year**

	NSW	VIC	QLD	SA	TAS	NT	ACT	NZ	ANZ
<b>2020</b>	4,350	4,211	3,395	1,294	356	80	405	3,156	17,247
<b>2021</b>	5,208	4,803	2,972	1,411	513	97	459	3,417	18,880
<b>2022</b>	6,174	4,867	3,366	1,174	761	114	495	3,599	20,550
<b>Total</b>	15,732	13,881	9,733	3,879	1,630	291	1,359	10,172	56,677

**Table S2: Age at diagnosis across ANZ by diagnosis year**

Year	Mean	95%CI	Median	25%	75%	Patients per year
2020	68.47	(68.34–68.60)	68.62	62.8	74.11	17,247
2021	68.7	(68.6–68.82)	68.77	62.81	74.67	18,880
2022	69.05	(68.94–69.17)	69.3	63.4	74.9	20,550

**Table S3: Age group at diagnosis by year as a percentage of total people registered in each year**

Diagnosis Year	Less than 60	60 to 64	65 to 69	70 to 74	Greater than 75	Total
<b>2020</b>	2,876/17,247	2,852/17,247	4,070/17,247	3,726/17,247	3,723/17,247	17,247
	<b>17%</b>	<b>17%</b>	<b>24%</b>	<b>22%</b>	<b>22%</b>	
<b>2021</b>	3,164/18,880	3,052/18,880	4,336/18,880	3,881/18,880	4,447/18,880	18,880
	<b>17%</b>	<b>16%</b>	<b>23%</b>	<b>21%</b>	<b>24%</b>	
<b>2022</b>	3,113/20,550	3,312/20,550	4,568/20,550	4,521/20,550	5,036/20,550	20,550
	<b>15%</b>	<b>16%</b>	<b>22%</b>	<b>22%</b>	<b>25%</b>	
<b>Total</b>	9,153/56,677	9,216/56,677	12,974/56,677	12,128/56,677	13,206/56,677	56,677
	<b>16%</b>	<b>16%</b>	<b>23%</b>	<b>21%</b>	<b>23%</b>	

**Table S4: Area of residency of registrants in PCOR-Australia by MMM**

Diagnosis Year	Metropolitan and Regional Centres	Rural towns and remote areas	Missing
<b>2020</b>	10,169/14,059	3,890/14,059	32/14,091
	<b>72%</b>	<b>28%</b>	0.23%
<b>2021</b>	11,038/15,442	4,404/15,442	21/15,463
	<b>71%</b>	<b>28%</b>	0.14%
<b>2022</b>	11,950/16,893	4,943/16,893	58/16,951
	<b>71%</b>	<b>29%</b>	0.34%
<b>Total</b>	33,157/46,394	13,237/46,394	111/46,505
	<b>71%</b>	<b>28%</b>	0.24%

Note: Metropolitan and regional centres includes MM1 and MM2. Rural towns and remote areas include MM3, MM4, MM5, MM6 and MM7 groups. Missing is defined as the number of registrants where a MMM couldn't be calculated, or the postcode doesn't have a MMM assigned, divided by the total number of registrants per year.

<b>Diagnosis Year</b>	<b>SES1</b>	<b>SES2</b>	<b>SES3</b>	<b>SES4</b>	<b>SES5</b>	<b>SES Invalid</b>
<b>2020</b>	2,325/14,042	2,206/14,042	2,576/14,042	2,804/14,042	4,131/14,042	49/14,091
	<b>16%</b>	<b>16%</b>	<b>18%</b>	<b>20%</b>	<b>29%</b>	<b>0.35%</b>
<b>2021</b>	2,412/15,414	2,398/15,414	2,799/15,414	3,188/15,414	4,617/15,414	49/15,463
	<b>16%</b>	<b>16%</b>	<b>18%</b>	<b>21%</b>	<b>30%</b>	<b>0.32%</b>
<b>2022</b>	2,549/16,868	2,689/16,868	3,239/16,868	3,438/16,868	4,953/16,868	83/16,951
	<b>15%</b>	<b>16%</b>	<b>19%</b>	<b>20%</b>	<b>29%</b>	<b>0.49%</b>
<b>Total</b>	7,286/46,324	7,293/46,324	8,614/46,324	9,430/46,324	13,701/46,324	181/46,505
	<b>16%</b>	<b>16%</b>	<b>19%</b>	<b>20%</b>	<b>29%</b>	<b>0.39%</b>

*Note: 181 patients could not be classified into an SES group. Percentages for SES1–SES5 are calculated as the number in each SES, divided by the total number with a known SES, per year. SES invalid percent is calculated as the number of people with an invalid/missing SES, divided by the total number of Australian registrants per year. Index of relative socio-economic advantage and disadvantage (IRSAD) is divided into quintiles, with quintile 1 (SES1) being the most socio-economically disadvantaged and quintile 5 (SES5) being the most socio-economically advantaged.*

**Table S6: PCOR-ANZ population coverage and incidence**

PCOR-ANZ population coverage										
	ACT	NSW	NT	NZ	QLD	SA	TAS	VIC	WA	Total†
<b>PCOR-ANZ 2015</b>	95	836	41	78	1,814	982	296	2,542	NA	6,684
Population diagnosed with prostate cancer in 2015	257	6,626	83	3,166	4,054	1,447	468	4,411	(1,975)	18,537
% population coverage	<b>36.97%</b>	<b>12.62%</b>	<b>49.40%</b>	<b>2.46%</b>	<b>44.75%</b>	<b>67.86%</b>	<b>63.25%</b>	<b>57.63%</b>	<b>NA</b>	<b>36.06%</b>
<b>PCOR-ANZ 2016</b>	218	2,156	82	260	1,519	972	397	2,839	NA	8,843
Population diagnosed with prostate cancer in 2016	260	6,492	86	3,487	4,000	1,370	544	4,847	(1,946)	19,140
% population coverage	<b>83.85%</b>	<b>33.21%</b>	<b>95.35%</b>	<b>7.46%</b>	<b>37.98%</b>	<b>70.95%</b>	<b>72.98%</b>	<b>58.57%</b>	<b>NA</b>	<b>46.20%</b>
<b>PCOR-ANZ 2017</b>	246	2,487	84	811	2,613	1,217	382	3,408	NA	11,248
Population diagnosed with prostate cancer in 2017	267	6,582	89	3,931	4,358	1,645	558	5,242	(2,120)	20,552
% population coverage	<b>92.14%</b>	<b>37.78%</b>	<b>94.38%</b>	<b>20.63%</b>	<b>59.96%</b>	<b>73.98%</b>	<b>68.46%</b>	<b>65.01%</b>	<b>NA</b>	<b>54.73%</b>
<b>PCOR-ANZ 2018</b>	322	3,853	66	1,900	3,161	1,175	358	3,894	NA	14,729
Population diagnosed with prostate cancer in 2018	270	7,036	89	4,258	4,787	1,688	567	5,231	(2,139)	21,787
% population coverage	<b>119.26%*</b>	<b>54.76%</b>	<b>74.16%</b>	<b>44.62%</b>	<b>66.03%</b>	<b>69.61%</b>	<b>63.14%</b>	<b>74.44%</b>	<b>NA</b>	<b>67.60%</b>
<b>PCOR-ANZ 2019</b>	380	3,790	98	2,886	3,431	1,417	305	4,628	NA	16,935
Population diagnosed with prostate cancer in 2019	294	6,886	96	4,268	4,889	2,023	564	6,064	(2,367)	22,717
% population coverage	<b>129.25%*</b>	<b>55.04%</b>	<b>102.08%*</b>	<b>67.62%</b>	<b>70.18%</b>	<b>70.04%</b>	<b>54.08%</b>	<b>76.32%</b>	<b>NA</b>	<b>74.60%</b>
<b>PCOR-ANZ 2020</b>	405	4,350	80	3,156	3,395	1,294	356	4,211	NA	17,247
Population diagnosed with prostate cancer in 2020	324	7,622	97	4,049	4,917	1,904	516	5,447	(2,465)	22,411
% population coverage	<b>125.00%*</b>	<b>57.07%</b>	<b>82.47%</b>	<b>77.95%</b>	<b>69.05%</b>	<b>67.96%</b>	<b>68.99%</b>	<b>77.31%</b>	<b>NA</b>	<b>76.96%</b>
2021										
	Reported national number <sup>#</sup>		PCOR-ANZ registrants		Percentage coverage per jurisdiction/country			Overall bi-national population coverage for PCOR-ANZ		
New Zealand	4,391		3,417		<b>77.82%</b>			18,880/28,128 67.23%		
Australia	23,737		15,463		<b>65.14%</b>					
2022										
New Zealand	4,334		3,599		<b>83.04%</b>			20,550/28,551 71.98%		
Australia	24,217		16,951		<b>70.00%</b>					

Notes: Estimated population coverage of the PCOR-ANZ data-set is based on the estimated prostate cancer incidence from the AIHW (updated 9th December 2024) (1) and the New Zealand Ministry of Health (2). The prostate cancer incidence estimation method used by the AIHW was changed in 2022 to better predict and reflect the aging nature of Australia's population, and this method will be the only one available from 2022 onwards. As a result, the data included for Australia in this report should not be compared to previous versions of the PCOR-ANZ annual report. These are only estimates and are not suitable for decision making. As of the time of this report, reporting of prostate cancer estimated incidence by

individual Australian states/territories was not available for 2021 and 2022. Therefore, for 2021 and 2022, the coverage for is for all of Australia (including Western Australia). The 2021 and 2022 values for New Zealand are correct at the time of writing.

Table\* In smaller jurisdictions (ACT and NT), the apparent coverage rate is >100%, which reflects people seeking care in jurisdictions other than where they ordinarily reside.

#Incidence (NZ) and Predicted/Projection (AUS). The reported number for Australia from the AIHW includes projected numbers for Western Australia within the estimate. However, it should be noted that Western Australia is not yet included as a jurisdiction in the PCOR-ANZ cohort.

†Total does not include the predicted value for Western Australia.

(1) <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/data> last updated 9<sup>th</sup> December 2024, accessed 10<sup>th</sup> February 2025. Cancer data in Australia, Australian Institute of Health and Welfare, Canberra, ACT, Australia).

(2) Cancer data and statistics – Te Whatu Ora - Health New Zealand. Accessed February 10, 2025. <https://www.tewhatauora.govt.nz/our-health-system/data-and-statistics/nz-health-statistics/health-statistics-and-data-sets/cancer-data-and-statistics/>

	Localised disease	Non-localised disease	% registrants with a missing NCCN who received a pre-biopsy MRI	% registrants who received a pre-biopsy MRI
<b>2015</b>	266/4,745 <b>5.6%</b>	22/506 <b>4.4%</b>	30/396 <b>7.6%</b>	318/5,647 <b>5.6%</b>
<b>2016</b>	1,192/6,125 <b>19.3%</b>	56/680 <b>8.2%</b>	88/586 <b>15.0%</b>	1,336/7,391 <b>18.1%</b>
<b>2017</b>	3,105/8,256 <b>37.6%</b>	172/947 <b>18.2%</b>	178/802 <b>22.2%</b>	3,455/10,005 <b>34.5%</b>
<b>2018</b>	5,632/10,866 <b>51.8%</b>	444/1,413 <b>31.4%</b>	268/1,047 <b>25.6%</b>	6,344/13,326 <b>47.6%</b>
<b>2019</b>	8,491/12,322 <b>68.9%</b>	639/1,521 <b>42.0%</b>	392/1,093 <b>35.9%</b>	9,522/14,936 <b>63.8%</b>
<b>2020</b>	8,511/11,976 <b>71.1%</b>	721/1,682 <b>42.9%</b>	492/1,320 <b>37.3%</b>	9,724/14,978 <b>64.9%</b>
<b>2021</b>	9,493/12,895 <b>73.6%</b>	783/1,671 <b>46.9%</b>	563/1,422 <b>39.6%</b>	10,839/15,988 <b>67.8%</b>
<b>2022</b>	10,709/13,692 <b>76.8%</b>	856/1,712 <b>50.0%</b>	665/1,380 <b>48.2%</b>	12,230/16,784 <b>72.9%</b>
<b>Total</b>	47,399/80,877 <b>58.6%</b>	3,693/10,132 <b>36.5%</b>	2,676/8,046 <b>33.3%</b>	53,768/99,055 <b>54.3%</b>

*Note: SA excluded from this presentation due to issues with data being migrated to the new database system. Localised disease: low, intermediate, high risk. Non-localised disease: regional or metastatic disease.*

		2020	2021	2022	TOTAL
<b>NSW</b>	Localised	2,586/3,296 <b>79%</b>	3,117/3,963 <b>79%</b>	3,769/4,537 <b>83%</b>	9,472/11,796 <b>80%</b>
	Non-localised	209/370 <b>56%</b>	258/409 <b>63%</b>	285/489 <b>58%</b>	752/1,268 <b>59%</b>
	NCCN unclassified	215/541 <b>40%</b>	268/700 <b>38%</b>	353/717 <b>49%</b>	836/1,958 <b>43%</b>
<b>VIC</b>	Localised	2,439/2,964 <b>82%</b>	2,628/3,122 <b>84%</b>	1,977/2,439 <b>81%</b>	7,044/8,525 <b>83%</b>
	Non-localised	195/465 <b>42%</b>	246/528 <b>47%</b>	195/389 <b>50%</b>	636/1,382 <b>46%</b>
	NCCN unclassified	101/296 <b>34%</b>	140/328 <b>43%</b>	136/287 <b>47%</b>	377/911 <b>41%</b>
<b>QLD</b>	Localised	2,125/2,519 <b>84%</b>	1,896/2,203 <b>86%</b>	2,518/2,780 <b>91%</b>	6,539/7,502 <b>87%</b>
	Non-localised	191/334 <b>57%</b>	110/171 <b>64%</b>	105/143 <b>73%</b>	406/648 <b>63%</b>
	NCCN unclassified	60/220 <b>27%</b>	20/98 <b>20%</b>	25/71 <b>35%</b>	105/389 <b>27%</b>
<b>TAS</b>	Localised	190/278 <b>68%</b>	259/401 <b>65%</b>	418/609 <b>69%</b>	867/1,288 <b>67%</b>
	Non-localised	13/50	24/76	45/95	82/221

		<b>26%</b>	<b>32%</b>	<b>47%</b>	<b>37%</b>
	NCCN unclassified	10/25	14/33	18/32	42/90
		<b>40%</b>	<b>42%</b>	<b>56%</b>	<b>47%</b>
<b>NT</b>	Localised	44/57	57/65	66/76	167/198
		<b>77%</b>	<b>88%</b>	<b>87%</b>	<b>84%</b>
	Non-localised	2/7	9/14	6/15	17/36
		<b>29%</b>	<b>64%</b>	<b>40%</b>	<b>47%</b>
	NCCN unclassified	8/14	12/15	15/22	35/51
		<b>57%</b>	<b>80%</b>	<b>68%</b>	<b>69%</b>
<b>ACT</b>	Localised	296/323	332/363	358/402	986/1,088
		<b>92%</b>	<b>91%</b>	<b>89%</b>	<b>91%</b>
	Non-localised	44/62	37/64	43/58	124/184
		<b>71%</b>	<b>58%</b>	<b>74%</b>	<b>67%</b>
	NCCN unclassified	6/20	22/32	21/35	49/87
		<b>30%</b>	<b>69%</b>	<b>60%</b>	<b>56%</b>
<b>NZ</b>	Localised	831/2,539	1,204/2,778	1,603/2,849	3,638/8,166
		<b>33%</b>	<b>43%</b>	<b>56%</b>	<b>45%</b>
	Non-localised	67/394	99/409	177/523	343/1,326
		<b>17%</b>	<b>24%</b>	<b>34%</b>	<b>26%</b>
	NCCN unclassified	92/204	87/216	97/216	276/636
		<b>45%</b>	<b>40%</b>	<b>45%</b>	<b>44%</b>
<b>AUS</b>	Localised	7,680/9,437	8,289/10,117	9,106/10,843	25,075/30,397
		<b>81%</b>	<b>82%</b>	<b>84%</b>	<b>82%</b>
	Non-localised	654/1,288	684/1,262	679/1,189	2,017/3,739
		<b>51%</b>	<b>54%</b>	<b>57%</b>	<b>54%</b>
	NCCN unclassified	400/1,116	476/1,206	568/1,164	1,444/3,486
		<b>36%</b>	<b>39%</b>	<b>49%</b>	<b>18%</b>
<b>ANZ</b>	Localised	8,511/11,976	9,493/12,895	10,709/13,692	28,713/38,563
		<b>71%</b>	<b>74%</b>	<b>78%</b>	<b>74%</b>
	Non-localised	721/1,682	783/1,671	856/1,712	2,360/5,065
		<b>43%</b>	<b>47%</b>	<b>50%</b>	<b>47%</b>
	NCCN unclassified	492/1,320	563/1,422	568/1,380	1,720/4,122
		<b>37%</b>	<b>40%</b>	<b>48%</b>	<b>42%</b>
<i>Note: SA excluded from this presentation due to issues with data being migrated to the new database system.</i>					

**Table S9: Proportion of registrants who received a biopsy at diagnosis by method and jurisdiction (2020–2022).**

	TRUS	Transperineal Biopsy	Other	Missing
NSW	1,891/15,679	10,735/15,679	3,053/15,679	53/15,732 (0.3%)
	<b>12%</b>	<b>68%</b>	<b>19%</b>	
VIC	475/11,611	9,666/11,611	1,470/11,611	2,270/13,881 (16%)
	<b>4%</b>	<b>83%</b>	<b>13%</b>	
QLD	1,703/9,179	6,716/9,179	760/9,179	554/9,733 (6%)
	<b>19%</b>	<b>73%</b>	<b>8%</b>	
SA	93/2,268	2,013/2,268	162/2,268	1,611/3,879 (42%)
	<b>4%</b>	<b>89%</b>	<b>7%</b>	
TAS	194/1,630	1,219/1,630	217/1,630	0/1,630 (0%)
	<b>12%</b>	<b>75%</b>	<b>13%</b>	
NT	205/282	43/282	34/282	9 /291 (3%)
	<b>73%</b>	<b>15%</b>	<b>12%</b>	
ACT	842/1,358	417/1,358	99/1,358	NC NC 0/1,359 (0%)
	<b>62%</b>	<b>31%</b>	<b>7%</b>	
NZ	6,326/10,167	2,767/10,167	1,074/10,167	5/10,172 (0.1%)
	<b>62%</b>	<b>27%</b>	<b>11%</b>	
Aus	5,403/42,007	30,809/42,007	5,795/42,007	4,498/46,505 (9.7%)
	<b>13%</b>	<b>73%</b>	<b>14%</b>	
ANZ	11,729/52,174	33,576/52,174	6,869/52,174	4,503/56,677 (8%)
	<b>22%</b>	<b>64%</b>	<b>13%</b>	

Notes: Percentages are calculated based on known diagnosis method. Other includes: TURP, TURBT, clinical investigation, histology of metastatic site, cystoprostatectomy, prostatectomy, other, 'Biopsy taken but unknown approach/not stated'. Missing includes: Unknown: at the point of data collection it is unknown whether a biopsy was taken. The missing column in this Table contains registrants who did not have the method of diagnosis data field completed or registrants who had unknown diagnosis as the method selected which is a valid data field option for a data collector to select. NC, not calculated due to low numbers (n<5).

**Table S10: Proportion of registrants who received a transperineal biopsy by jurisdiction or country, over time (2020–2022)**

Year	NSW	VIC	QLD	SA	TAS	NT	ACT	NZ	AUS	ANZ
2020	<b>82%</b>	<b>93%</b>	<b>66%</b>	<b>90%</b>	<b>92%</b>	<b>NC</b>	<b>10%</b>	<b>24%</b>	<b>79%</b>	<b>68%</b>
	2,675/ 3,281	3,102/ 3,319	1,954/ 2,959	679/756	278/302	NC	35/365	691/ 2,860	8,725/ 11,049	9,416/ 13,909
2021	<b>86%</b>	<b>96%</b>	<b>83%</b>	<b>97%</b>	<b>80%</b>	<b>22%</b>	<b>18%</b>	<b>29%</b>	<b>86%</b>	<b>74%</b>
	3,465/ 4,015	3,549/ 3,701	1,944/ 2,337	345/356	362/451	18/83	78/433	886/ 3,068	9,761/ 11,376	10,647/ 14,444
2022	<b>86%</b>	<b>97%</b>	<b>90%</b>	<b>100%</b>	<b>88%</b>	<b>23%</b>	<b>66%</b>	<b>38%</b>	<b>90%</b>	<b>80%</b>
	4,595/ 5,330	3,015/ 3,121	2,818/ 3,123	989/994	579/660	23/98	304/461	1,190/ 3,165	12,323/ 13,787	13,513/ 16,952
Total	<b>85%</b>	<b>95%</b>	<b>80%</b>	<b>96%</b>	<b>86%</b>	<b>17%</b>	<b>33%</b>	<b>30%</b>	<b>85%</b>	<b>74%</b>
	10,735/ 12,626	9,666/ 10,141	6,716/ 8,419	2,013/ 2,106	1,219/ 1,413	43/248	417/ 1,259	2,767/ 9,093	30,809/ 36,212	33,576/ 45,305

Note: Calculated as the number of transperineal biopsies divided by the number of transperineal AND transrectal ultrasound guided biopsies (TRUS). The numerator is therefore the number of transperineal biopsies, and the denominator the number of transperineal and TRUS biopsies added together. NC, not calculated due to low numbers (n<5).

**Table S11: Median PSA of PCOR-ANZ registrants at diagnosis by jurisdiction (2020–2022)**

Jurisdiction	Median (IQR) PSA ng/ml	Missing
<b>NSW</b> (N=15,732)	7.03 (5.00 – 10.80) (n=12,631)	3,101 (20%)
<b>VIC</b> (N=13,881)	7.40 (5.16 – 11.82) (n=9,708)	4,173 (30%)
<b>QLD</b> (N=9,733)	6.50 (4.60 – 9.50) (n=8,127)	1,606 (17%)
<b>SA</b> (N=3,879)	7.90 (5.43 – 12.04) (n=3,236)	643 (17%)
<b>TAS</b> (N=1,630)	8.40 (5.90 – 12.50) (n=1,526)	104 (6%)
<b>NT</b> (N=291)	9.00 (5.93 – 16.00) (n=220)	71 (24%)
<b>ACT</b> (N=1,359)	7.40 (5.30 – 11.18) (n=1,242)	117 (9%)
<b>NZ</b> (N=10,172)	8.00 (5.50 – 14.20) (n=9,340)	832 (8%)
<b>AUS</b> (N=46,505)	7.15 (5.00 – 11.00) (n=36,690)	9,815 (21%)
<b>ANZ</b> (N=56,677)	7.30 (5.10 – 11.40) (n=46,030)	10,647 (19%)
<b>Mean PSA in PCOR-ANZ</b>		
	<b>Mean</b>	<b>95 CI %</b>
<b>ANZ</b> (N=46,030)	31.55	(29.27 – 33.84)

**Table S12: Proportion of registrants grouped by PSA level at diagnosis (2020–2022)**

	PSA level ≤3 ng/mL	PSA level >3 ng/mL to <10 ng/mL	PSA level ≥10 ng/mL to <20 ng/mL	PSA level ≥20 ng/mL to <50 ng/mL	PSA level ≥50ng/mL	No documented PSA recorded within 6 months of diagnosis
<b>2020</b>	871/14,426	9,041/14,426	2,716/14,426	1,039/14,426	759/14,426	2,821/17,247
	<b>6.0%</b>	<b>63%</b>	<b>19%</b>	<b>7.2%</b>	<b>5.3%</b>	<b>16%</b>
<b>2021</b>	904/15,468	9,795/15,468	2,832/15,468	1,121/15,468	816/15,468	3,412/18,880
	<b>5.8%</b>	<b>63%</b>	<b>18%</b>	<b>7.2%</b>	<b>5.3%</b>	<b>18%</b>
<b>2022</b>	870/16,136	10,340/16,136	3,022/16,136	1,135/16,136	769/16,136	4,414/20,550
	<b>5.4%</b>	<b>64%</b>	<b>19%</b>	<b>7.0%</b>	<b>4.8%</b>	<b>21%</b>
<b>Total</b>	2,645/46,030	29,176/46,030	8,570/46,030	3,295/46,030	2,344/46,030	10,647/56,677
	<b>5.7%</b>	<b>63%</b>	<b>19%</b>	<b>7.2%</b>	<b>5.1%</b>	<b>19%</b>

	ISUP GRADE 1	ISUP GRADE 2	ISUP GRADE 3	ISUP GRADE 4	ISUP GRADE 5	Missing
<b>2020</b>	3,750/15,558	4,786/15,558	2,622/15,558	1,709/15,558	2,691/15,558	1,689/17,247
	<b>24%</b>	<b>31%</b>	<b>17%</b>	<b>11%</b>	<b>17%</b>	<b>10%</b>
<b>2021</b>	3,633/16,101	5,166/16,101	2,841/16,101	1,579/16,101	2,882/16,101	2,779/18,880
	<b>23%</b>	<b>32%</b>	<b>18%</b>	<b>10%</b>	<b>18%</b>	<b>15%</b>
<b>2022</b>	3,645/17,156	5,583/17,156	3,065/17,156	1,823/17,156	3,040/17,156	3,394/20,550
	<b>21%</b>	<b>33%</b>	<b>18%</b>	<b>11%</b>	<b>18%</b>	<b>17%</b>
<b>Total</b>	11,028/48,815	15,535/48,815	8,528/48,815	5,111/48,815	8,613/48,815	7,862/56,677
	<b>23%</b>	<b>32%</b>	<b>18%</b>	<b>11%</b>	<b>18%</b>	<b>14%</b>

*Note: The proportions calculated in this table do not include missing data in the denominator.*

	ISUP GRADE 1	ISUP GRADE 2	ISUP GRADE 3	ISUP GRADE 4	ISUP GRADE 5	Missing ISUP (%)
<b>NSW</b>	2,854/15,551	5,073/15,551	2,901/15,551	1,731/15,551	2,992/15,551	181/15,732
	<b>18%</b>	<b>33%</b>	<b>19%</b>	<b>11%</b>	<b>19%</b>	(1%)
<b>VIC</b>	2,481/10,306	3,512/10,306	1,730/10,306	856/10,306	1,727/10,306	3,575/13,881
	<b>24%</b>	<b>34%</b>	<b>17%</b>	<b>8%</b>	<b>17%</b>	(26%)
<b>QLD</b>	1,388/8,473	2,767/8,473	1,651/8,473	795/8,473	1,872/8,473	1,260/9,733
	<b>16%</b>	<b>33%</b>	<b>19%</b>	<b>9%</b>	<b>22%</b>	(13%)
<b>SA</b>	442/1,534	421/1,534	246/1,534	174/1,534	251/1,534	2,345/3,879
	<b>29%</b>	<b>27%</b>	<b>16%</b>	<b>11%</b>	<b>16%</b>	(60%)
<b>TAS</b>	577/1,598	461/1,598	213/1,598	164/1,598	183/1,598	32/1,630
	<b>36%</b>	<b>29%</b>	<b>13%</b>	<b>10%</b>	<b>11%</b>	(2%)
<b>NT</b>	68/270	50/270	61/270	45/270	46/270	21/291
	<b>25%</b>	<b>19%</b>	<b>23%</b>	<b>17%</b>	<b>17%</b>	(7%)
<b>ACT</b>	314/1,332	443/1,332	216/1,332	177/1,332	182/1,332	27/1,359
	<b>24%</b>	<b>33%</b>	<b>16%</b>	<b>13%</b>	<b>14%</b>	(2%)
<b>NZ</b>	2,904/9,751	2,808/9,751	1,510/9,751	1,169/9,751	1,360/9,751	421/10,172
	<b>30%</b>	<b>29%</b>	<b>15%</b>	<b>12%</b>	<b>14%</b>	(4%)
<b>AUS</b>	8,124/39,064	12,727/39,064	7,018/39,064	3,942/39,064	7,253/39,064	7,441/46,505
	<b>21%</b>	<b>33%</b>	<b>18%</b>	<b>10%</b>	<b>19%</b>	(16%)
<b>ANZ</b>	11,028/48,815	15,535/48,815	8,528/48,815	5,111/48,815	8,613/48,815	7,862/56,677
	<b>23%</b>	<b>32%</b>	<b>17%</b>	<b>10%</b>	<b>18%</b>	(14%)

*Note: The proportions calculated in this table do not include missing data in the denominator.*

**Table S15: Proportion of registrants per clinical TNM group at diagnosis (2020–2022)**

	T1N0M0	T2N0M0	T3N0M0	T4N0M0	TxN1M0	TxNxM1	Missing
2020	4,978/ 10,359	2,862/ 10,359	769/ 10,359	39/ 10,359	550/ 10,359	1,161/ 10,359	6,888/ 17,271 (40%)
	<b>48%</b>	<b>28%</b>	<b>7%</b>	<b>0.38%</b>	<b>5%</b>	<b>11%</b>	
2021	5,041/ 10,423	2,961/ 10,423	711/ 10,423	35/ 10,423	537/ 10,423	1,138/ 10,423	8,457/ 18,880 (45%)
	<b>48%</b>	<b>28%</b>	<b>7%</b>	<b>0.34%</b>	<b>5%</b>	<b>11%</b>	
2022	5,260/ 11,300	3,431/ 11,300	850/ 11,300	35/ 11,300	586/ 11,300	1,138/ 11,300	9,250/ 20,550 (45%)
	<b>47%</b>	<b>30%</b>	<b>8%</b>	<b>0.31%</b>	<b>5%</b>	<b>10%</b>	
Total	15,279/ 32,082	9,254/ 32,082	2,330/ 32,082	109/ 32,082	1,673/ 32,082	3,437/ 32,082	24,595/ 56,677 (43%)
	<b>48%</b>	<b>29%</b>	<b>7%</b>	<b>0.34%</b>	<b>5%</b>	<b>11%</b>	

Note: The proportions calculated in this table do not include missing data in the denominator.

**Table S16: Proportion of registrants per clinical TNM group at diagnosis, by jurisdiction or country (2020–2022)**

	T1N0M0	T2N0M0	T3N0M0	T4N0M0	TxN1M0	TxNxM1	Missing
NSW	3,232/7,763	2,363/7,763	837/7,763	36/7,763	528/7,763	767/7,763	7,969/15,732 51%
	<b>42.63%</b>	<b>30%</b>	<b>11%</b>	<b>0.46%</b>	<b>7%</b>	<b>9.9%</b>	
VIC	2,938/6,563	1,772/6,563	456/6,563	21/6,563	355/6,563	1,021/6,563	7,318/13,881 53%
	<b>45%</b>	<b>27%</b>	<b>7%</b>	<b>0.32%</b>	<b>5%</b>	<b>15.6%</b>	
QLD	3,747/6,841	2,067/6,841	359/6,841	19/6,841	285/6,841	364/6,841	2,892/9,733 30%
	<b>55%</b>	<b>30%</b>	<b>5%</b>	<b>0.28%</b>	<b>4%</b>	<b>5.3%</b>	
SA	390/1,228	639/1,228	157/1,228	NC	12/1,228	28/1,228	2,651/3,879 68%
	<b>32%</b>	<b>52%</b>	<b>13%</b>	<b>NC</b>	<b>1%</b>	<b>2.3</b>	
TAS	518/1,269	451/1,269	86/1,269	NC	77/1,269	137/1,269	357/1,626 22%
	<b>41%</b>	<b>35%</b>	<b>7%</b>	<b>NC</b>	<b>6.1%</b>	<b>11%</b>	
NT	34/139	48/139	25/139	NC	10/139	22/139	152/291 52%
	<b>24%</b>	<b>35%</b>	<b>18%</b>	<b>NC</b>	<b>7.2%</b>	<b>16%</b>	
ACT	141/549	147/549	77/549	NC	77/549	107/549	809/1,359 60%
	<b>26%</b>	<b>27%</b>	<b>14%</b>	<b>NC</b>	<b>14%</b>	<b>19%</b>	
NZ	4,279/7,725	1,767/7,725	333/7,725	26/7,725	329/7,725	991/7,725	2,447/10,172 24%
	<b>55%</b>	<b>23%</b>	<b>4%</b>	<b>0.34%</b>	<b>4.3%</b>	<b>13%</b>	
AUS	11,000/24,357	7,487/24,357	1,997/24,357	83/24,357	1,344/24,357	2,446/24,357	22,148/46,505 48%
	<b>45%</b>	<b>31%</b>	<b>8%</b>	<b>0.34%</b>	<b>5.5%</b>	<b>10%</b>	
ANZ	15,279/32,082	9,254/32,082	2,330/32,082	109/32,082	1,673/32,082	3,437/32,082	24,595/56,677 43%
	<b>48%</b>	<b>29%</b>	<b>7%</b>	<b>0.34%</b>	<b>5.2%</b>	<b>11%</b>	

Note: The proportions calculated in this table do not include missing data in the denominator. NC – Not calculated due to low numbers. NC, not calculated due to low numbers (n<5).

Year	Low	Intermediate	High	Regional	Metastatic	Missing
2020	2,613/ 14,524	6,361/ 14,524	3,825/ 14,524	564/ 14,524	1,161/ 14,524	2,723/17,247 16%
	<b>18%</b>	<b>44%</b>	<b>26%</b>	<b>3.9%</b>	<b>8.0%</b>	
2021	2,560/ 15,071	6,837/ 15,071	3,980/ 15,071	556/ 15,071	1,138/ 15,071	3,809/18,880 20%
	<b>17%</b>	<b>45%</b>	<b>26%</b>	<b>3.7%</b>	<b>7.6%</b>	
2022	2,554/ 16,076	7,350/ 16,076	4,426/ 16,076	608/ 16,076	1,138/ 16,076	4,474/20,550 22%
	<b>16%</b>	<b>46%</b>	<b>28%</b>	<b>3.8%</b>	<b>7.1%</b>	
TOTAL	7,727/ 45,671	20,548/ 45,671	12,231/ 45,671	1,728/ 45,671	3,437/ 45,671	11,006/56,677 20%
	<b>17%</b>	<b>45%</b>	<b>27%</b>	<b>3.8%</b>	<b>7.5%</b>	

*Note: The proportions calculated in this table do not include missing data in the denominator.*

	Low	Intermediate	High	Regional	Metastatic	Missing
NSW	1,843/13,439	6,128/13,439	4,167/13,439	534/13,439	767/13,439	2,293/15,732 15%
	<b>14%</b>	<b>46%</b>	<b>31%</b>	<b>4%</b>	<b>6%</b>	
VIC	1,797/9,925	4,578/9,925	2,159/9,925	370/9,925	1,021/9,925	3,956/13,881 29%
	<b>18%</b>	<b>46%</b>	<b>22%</b>	<b>4%</b>	<b>10%</b>	
QLD	1,053/8,165	4,147/8,165	2,314/8,165	287/8,165	364/8,165	1,568/9,733 16%
	<b>13%</b>	<b>51%</b>	<b>28%</b>	<b>4%</b>	<b>4%</b>	
SA	297/1,576	531/1,576	698/1,576	22/1,576	28/1,576	2,303/3,879 59%
	<b>19%</b>	<b>34%</b>	<b>44%</b>	<b>1%</b>	<b>2%</b>	
TAS	384/1,536	628/1,536	300/1,536	87/1,536	137/1,536	94/1,630 6%
	<b>25%</b>	<b>41%</b>	<b>20%</b>	<b>6%</b>	<b>9%</b>	
NT	35/237	82/237	84/237	14/237	22/237	54/291 19%
	<b>15%</b>	<b>35%</b>	<b>35%</b>	<b>6%</b>	<b>9%</b>	
ACT	232/1,272	555/1,272	301/1,272	77/1,272	107/1,272	87/1,359 6%
	<b>18%</b>	<b>44%</b>	<b>24%</b>	<b>6%</b>	<b>8%</b>	
AUS	5,641/36,150	16,649/36,150	10,023/36,150	1,391/36,150	2,446/36,150	10,355/46,505 22%
	<b>16%</b>	<b>46%</b>	<b>28%</b>	<b>4%</b>	<b>7%</b>	
NZ	2,086/9,521	3,899/9,521	2,208/9,521	337/9,521	991/9,521	651/10,172 6.4%
	<b>22%</b>	<b>41%</b>	<b>23%</b>	<b>4%</b>	<b>10%</b>	
ANZ	7,727/45,671	20,548/45,671	12,231/45,671	1,728/45,671	3,437/45,671	11,006/56,677 19%
	<b>17%</b>	<b>45%</b>	<b>27%</b>	<b>4%</b>	<b>8%</b>	

*Note: The proportions calculated in this table do not include missing data in the denominator*

**Table S19: Proportion of registrants with an NCCN risk group at diagnosis, by SES group (2020–2022)**

	Low	Intermediate	High	Regional	Metastatic	Missing
SES1	821/5,568	2,401/5,568	1,697/5,568	253/5,568	396/5,568	1,718/7,286
	<b>15%</b>	<b>43%</b>	<b>30%</b>	<b>4.5%</b>	<b>7.1%</b>	23%
SES2	846/5,735	2,603/5,735	1,686/5,735	223/5,735	377/5,735	1,558/7,293
	<b>15%</b>	<b>45%</b>	<b>29%</b>	<b>3.9%</b>	<b>6.6%</b>	21%
SES3	1,092/6,708	3,110/6,708	1,800/6,708	256/6,708	450/6,708	1,906/8,614
	<b>16%</b>	<b>46%</b>	<b>27%</b>	<b>3.8%</b>	<b>6.7%</b>	22%
SES4	1,138/7,173	3,293/7,173	1,952/7,173	263/7,173	527/7,173	2,257/9,430
	<b>16%</b>	<b>46%</b>	<b>27%</b>	<b>3.7%</b>	<b>7.4%</b>	24%
SES5	1,731/10,838	5,174/10,838	2,850/10,838	392/10,838	691/10,838	2,863/13,701
	<b>16%</b>	<b>48%</b>	<b>26%</b>	<b>3.6%</b>	<b>6.4%</b>	21%
Total	5,628/36,022	16,581/36,022	9,985/36,022	1,387/36,022	2,441/36,022	10,302/46,324
	<b>16%</b>	<b>46%</b>	<b>28%</b>	<b>3.9%</b>	<b>6.8%</b>	22%

*Note: 183 Registrants had SES Unclassified. The proportions calculated in this table do not include missing data in the denominator.*

3 Management

**Table S20: Proportion of registrants with an NCCN risk group at diagnosis, by diagnosis year and initial management provided (2020–2022)**

	Surgery	RT–ADT	RT+ADT	ADT+/-Chemo	Active Surveillance	Watchful Waiting	Total
<b>Low risk</b>							
2020	341	63	10	7	2,044	65	2,530
	<b>13%</b>	<b>2.49%</b>	<b>0.40%</b>	<b>0.28%</b>	<b>81%</b>	<b>2.6%</b>	<b>100%</b>
2021	316	68	8	14	1,983	52	2,441
	<b>13%</b>	<b>2.8%</b>	<b>0.33%</b>	<b>0.57%</b>	<b>81%</b>	<b>2.1%</b>	<b>100%</b>
2022	211	61	9	7	2,040	63	2,391
	<b>8.8%</b>	<b>2.6%</b>	<b>0.38%</b>	<b>0.29%</b>	<b>85%</b>	<b>2.6%</b>	<b>100%</b>
Total	868	192	27	28	6,067	180	7,362
	<b>12%</b>	<b>2.6%</b>	<b>0.37%</b>	<b>0.38%</b>	<b>82%</b>	<b>2.4%</b>	<b>100%</b>
<b>Intermediate risk</b>							
2020	3,594	848	573	101	855	141	6,112
	<b>59%</b>	<b>14%</b>	<b>9.4%</b>	<b>1.7%</b>	<b>14%</b>	<b>2.3%</b>	<b>100%</b>
2021	3,779	1,002	602	79	858	144	6,464
	<b>58%</b>	<b>16%</b>	<b>9.3%</b>	<b>1.2%</b>	<b>13%</b>	<b>2.2%</b>	<b>100%</b>
2022	3,782	1,206	589	77	989	158	6,801
	<b>56%</b>	<b>18%</b>	<b>8.7%</b>	<b>1.1%</b>	<b>15%</b>	<b>2.3%</b>	<b>100%</b>
Total	11,155	3,056	1,764	257	2,702	443	19,377
	<b>58%</b>	<b>16%</b>	<b>9.1%</b>	<b>1.3%</b>	<b>14%</b>	<b>2.3%</b>	<b>100%</b>
<b>High risk</b>							
2020	1,654	243	1,145	348	97	106	3,593
	<b>46%</b>	<b>6.76%</b>	<b>32%</b>	<b>9.7%</b>	<b>2.7%</b>	<b>2.9%</b>	<b>100%</b>
2021	1,672	321	1,160	337	66	91	3,647
	<b>46%</b>	<b>8.8%</b>	<b>32%</b>	<b>9.2%</b>	<b>1.8%</b>	<b>2.5%</b>	<b>100%</b>
2022	1,866	428	1,165	331	84	107	3,981
	<b>47%</b>	<b>10.75%</b>	<b>29%</b>	<b>8.3%</b>	<b>2.1%</b>	<b>2.7%</b>	<b>100%</b>
Total	5,192	992	3,470	1,016	247	304	11,221
	<b>46%</b>	<b>8.84%</b>	<b>31%</b>	<b>9.1%</b>	<b>2.2%</b>	<b>2.7%</b>	<b>100%</b>
<b>Regional</b>							
2020	96	25	274	140	NC	9	546
	<b>18%</b>	<b>4.6%</b>	<b>50%</b>	<b>26%</b>	<b>NC</b>	<b>1.7%</b>	<b>100%</b>
2021	78	34	298	126	NC	NC	540
	<b>14%</b>	<b>6.3%</b>	<b>55%</b>	<b>23%</b>	<b>NC</b>	<b>NC</b>	<b>100%</b>
2022	78	52	321	125	NC	5	582
	<b>13%</b>	<b>8.9%</b>	<b>55%</b>	<b>21%</b>	<b>NC</b>	<b>0.86%</b>	<b>100%</b>
Total	252	111	893	391	NC	18	1,668
	<b>15%</b>	<b>6.7%</b>	<b>54%</b>	<b>23%</b>	<b>NC</b>	<b>1.08%</b>	<b>100%</b>
<b>Metastatic</b>							
2020	33	24	374	683	6	9	1,129
	<b>2.9%</b>	<b>2.1%</b>	<b>33%</b>	<b>61%</b>	<b>0.53%</b>	<b>0.8%</b>	<b>100%</b>
2021	22	27	344	695	NC	6	1,097
	<b>2.0%</b>	<b>2.5%</b>	<b>31%</b>	<b>63%</b>	<b>NC</b>	<b>0.55%</b>	<b>100%</b>
2022	28	40	363	652	NC	NC	1,089
	<b>2.6%</b>	<b>3.7%</b>	<b>33%</b>	<b>60%</b>	<b>NC</b>	<b>NC</b>	<b>100%</b>
Total	83	91	1,081	2,030	13	17	3,315
	<b>2.5%</b>	<b>2.8%</b>	<b>33%</b>	<b>61%</b>	<b>0.39%</b>	<b>0.51%</b>	<b>100%</b>

Notes: Primary treatment by NCCN classification and diagnosis year. Percentages are per row. NC, not calculated due to low numbers (n<5).

**Table S21: Proportion of registrants receiving active surveillance by NCCN group and age group (2020–2022)**

	<60	≥60 to <65	≥65 to <70	≥70 to <75	≥75	Total
<b>Low</b>	1,644/2,031 <b>80.95%</b>	1,364/1,640 <b>83.17%</b>	1,643/1,940 <b>84.69%</b>	949/1,139 <b>83.32%</b>	467/612 <b>76.31%</b>	6,067/7,362 <b>82.41%</b>
<b>Intermediate</b>	333/3,573 <b>9.32%</b>	397/3,591 <b>11.06%</b>	619/4,931 <b>12.55%</b>	676/4,150 <b>16.29%</b>	677/3,132 <b>21.62%</b>	2,702/19,377 <b>13.94%</b>

Note: Patients with low/intermediate risk disease who remained on AS for 1 year and 1 day will appear in this Table.

**Table S22: Proportion of registrants with low-, intermediate- or high-risk prostate cancer who received AS at 12 months by diagnosis year and by ISUP grade (2020–2022)**

	ISUP Grade 1	ISUP Grade 2
<b>2020</b>	2,354/2,986 <b>79%</b>	551/4,042 <b>14%</b>
<b>2021</b>	2,280/2,863 <b>80%</b>	541/4,278 <b>13%</b>
<b>2022</b>	2,362/2,825 <b>84%</b>	638/4,505 <b>14%</b>

Note: Only patients classified to low/intermediate/high risk disease, who received active surveillance, and who had an ISUP grade of 1 or 2 will appear here.

**Table S23: Proportion of registrants who initially received active surveillance and then switched to active treatment within 12 months of diagnosis**

<b>Registrants with <u>low-risk disease</u></b>				
	0-<3 months	3-<6months	6-<9 months	9-12 months
<b>On active surveillance</b>	6,352/6,358 <b>99.91%</b>	6,323/63,58 <b>99.45%</b>	6,233/6,358 <b>98.03%</b>	6,067/6,358 <b>95.42%</b>
<b>Switched to an active treatment during that time period (not cumulative)</b>	6/6,358 <b>0.09%</b>	29/6,358 <b>0.46%</b>	90/6,358 <b>1.42%</b>	166/6,358 <b>2.61%</b>
<b>Switched to an active treatment (cumulative)</b>	6/6,358 <b>0.09%</b>	35/6,358 <b>0.55%</b>	125/6,358 <b>1.97%</b>	291/6,358 <b>4.58%</b>
<b>Registrants with <u>intermediate risk disease</u></b>				
	0-<3 months	3-<6months	6-<9 months	9-12 months
<b>On active surveillance</b>	2,886/2,897 <b>99.62%</b>	2,852/2,897 <b>98.45%</b>	2,788/2,897 <b>96.24%</b>	2,703/2,897 <b>93.30%</b>
<b>Switched to an active treatment during that time period (not cumulative)</b>	11/2,897 <b>0.38%</b>	34/2,897 <b>1.17%</b>	64/2,897 <b>2.21%</b>	85/2,897 <b>2.93%</b>
<b>Switched to an active treatment (cumulative)</b>	11/2,897 <b>0.38%</b>	45/2,897 <b>1.55%</b>	109/2,897 <b>3.76%</b>	194/2,897 <b>6.70%</b>

Notes: active treatment includes surgery/RT alone/RT+ADT/ADT-/+ chemo). Denominator: Patients who had at least 1 day of being assigned to active surveillance and had low- or intermediate-risk disease. Numerator (on active surveillance): Patients who were still on active surveillance during the defined period range. Numerator (switched to an active treatment): Patients within that period who switched from active surveillance to active treatment during that period.

**Table S24: Proportion of registrants receiving surgery within 90 days of diagnosis by NCCN group across ANZ (2020–2022)**

	Less than or equal to 90 days	Greater than 90 days	Total
Low risk	303	565	868
	35%	65%	100%
Intermediate risk	6,465	4,690	11,155
	58%	42%	100%
High risk	3,565	1,624	5,189
	69%	31%	100%
Total	10,333	6,879	17,212
	60%	40%	100%

*Note: Proportion of patients who received surgery within 90 days of diagnosis, stratified by NCCN risk group. This is calculated as the time between diagnosis and surgery.*

**Table S25: Proportion of registrants receiving surgery by treating institute type**

	Private Surgery	Public Surgery
ANZ	74% (13,846/18,810)	26% (4,964/18,810)
Australia	79% (12,464/15,672)	21% (3,208/15,672)
New Zealand	44% (1,382/3,178)	56% (1,756/3,178)

*Note: 166 patients who were treated in a surgical institute where the institute type was unknown or other will not appear in this Table.*

**Table S26: Proportion of registrants receiving surgery within 90 days of diagnosis by treating surgical institute in Australia and New Zealand (2020–2022)**

NCCN group by Surgical institute type	Less than or equal to 90 days	Greater than 90 days	Total	% Meets criteria
Low risk and treated in a public institution	37	236	273	14%
Low risk and treated in a private institution	261	321	582	45%
Intermediate and treated in a public institution	675	2,104	2,779	24%
Intermediate risk and treated in a private institution	5,737	2,527	8,264	69%
High risk and treated in a public institution	465	903	1,368	34%
High risk and treated in a private institution	3,057	704	3,761	81%
Localised and treated in a private institution	1,177	3,243	4,420	27%
Localised and treated in a public institution	9,055	3,552	12,607	72%

*Note: Proportion of patients who received surgery within 90 days of diagnosis, stratified by NCCN risk group and institution type (private/public). This is calculated as the time between diagnosis and surgery. Australian and New Zealand patients.*

**Table S27: Proportion of registrants receiving surgery within 90 days of diagnosis by treating surgical institute in Australia (public/private) (2020–2022)**

NCCN group by Surgical institute type	Less than or equal to 90 days	Greater than 90 days	Total	% Meets criteria
Low risk and treated in a public institution	26	128	154	17%
Low risk and treated in a private institution	208	251	459	45%
Intermediate risk and treated in a public institution	406	1,288	1,694	24%
Intermediate risk and treated in a private institution	5,174	2,185	7,359	70%
High risk and treated in a public institution	311	600	911	34%
High risk and treated in a private institution	2,848	636	3,484	82%
Localised and treated in a public institution	743	2,016	2,759	27%
Localised and treated in a private institution	8,230	3,072	11,302	73%

*Note: Proportion of patients who received surgery within 90 days of diagnosis, stratified by NCCN risk group and institution type (private/public). This is calculated as the time between diagnosis and surgery. Australian patients only.*

**Table S28: Proportion of registrants receiving surgery within 90 days of diagnosis by treating surgical institute in New Zealand (2020–2022)**

NCCN group by Surgical institute type	Less than or equal to 90 days	Greater than 90 days	Total	% Meets criteria
Low risk and treated in a public institution	11	108	119	9%
Low risk and treated in a private institution	53	70	123	43%
Intermediate risk and treated in a public institution	269	816	1,085	25%
Intermediate risk and treated in a private institution	563	343	906	62%
High risk and treated in a public institution	154	303	457	34%
High risk and treated in a private institution	210	70	280	75%
Localised and treated in a public institution	434	1,227	1,661	26%
Localised and treated in a private institution	826	483	1,309	63%

*Note: Proportion of patients who received surgery within 90 days of diagnosis, stratified by NCCN risk group and institution type (private/public). This is calculated as the time between diagnosis and surgery. New Zealand patients only.*

**Table S29: Proportion of registrants receiving surgery within 90 days of diagnosis by SES and surgical institute (Australia only; 2020–2022)**

	Public		Private		Institute type Other or Unknown	
	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days
<b>SES1 (Low)</b>	145/677 21%	532/677 79%	853/1,347 63%	494/1,347 37%	13/19 68%	6/19 32%
<b>SES2</b>	171/636 27%	465/636 73%	1,139/1,688 68%	549/1,688 33%	16/31 52%	15/31 48%
<b>SES3</b>	190/715 27%	525/715 73%	1,324/1,975 67%	651/1,975 33%	19/33 58%	14/33 42%
<b>SES4</b>	168/601 28%	433/601 72%	1,985/2,658 75%	673/2,658 25%	16/26 62%	10/26 38%
<b>SES5 (High)</b>	168/568 30%	400/568 70%	3,752/4,757 79%	1,005/4,757 21%	38/53 72%	15/53 28%
<b>Total</b>	842/3,197 26%	2,355/3,197 74%	9,053/12,425 73%	3,372/12,425 27.4%	102/162 63%	60/162 37%

*Note: 51 registrants were unable to be classified into an SES group. Proportion of patients who received surgery within 90 days of diagnosis, stratified by SES group and institution type (private/public/other unknown). This is calculated as the time between diagnosis and surgery. Australian residents only.*

**Table S30: Proportion of registrants receiving RT alone within 90 days of diagnosis by NCCN group (2020–2022)**

	Less than or equal to 90 days	Greater than 90 days	Total
<b>Low risk</b>	44	148	192
	23%	77%	100%
<b>Intermediate risk</b>	992	2,060	3,052
	33%	68%	100%
<b>High risk</b>	310	672	982
	32%	68%	100%
<b>Total</b>	1,346	2,880	4,226
	32%	68%	100%

*Note: Proportion of patients who received radiotherapy alone within 90 days of diagnosis, stratified by NCCN risk classification. This is calculated as the time between diagnosis and commencement of radiation (external beam or brachytherapy).*

**Table S31: Proportion of registrants receiving RT+ADT within 90 days of diagnosis by NCCN group (2020–2022)**

	Less than or equal to 90 days	Greater than 90 days	Total
Low Risk	8	19	27
	30%	70%	100%
Intermediate Risk	1,262	488	1,750
	72%	28%	100%
High Risk	2,805	615	3,420
	82%	18%	100%
Regional Disease	766	110	876
	87%	13%	100%
Metastatic Disease	883	70	953
	93%	7%	100%
Missing	113	66	179
	63%	37%	100%
Total	5,837	1,368	7,205
	81%	19%	100%

*Note: Proportion of patients who received radiotherapy with ADT within 90 days of diagnosis, stratified by NCCN risk group. This is calculated as the time between diagnosis and the commencement of radiation (external beam or brachytherapy) or first ADT administration, whichever came first. Missing refers to patients where an NCCN classification could not be calculated.*

**Table S32: Proportion of registrants receiving RT alone within 90 days of diagnosis by SES group (2020–2022)**

	Public		Private		Institute type Other or Unknown	
	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days
SES1	67/482 14%	415/482 86%	79/215 37%	136/215 63%	4/47 8.5%	43/47 91%
SES2	61/324 19%	263/324 81%	124/294 42%	170/294 58%	4/51 14%	44/51 86%
SES3	79/440 18%	361/440 82%	153/388 40%	235/388 61%	8/43 19%	35/43 81%
SES4	82/352 23%	270/352 77%	187/382 49%	195/382 51%	11/41 27%	30/41 73%
SES5	117/421 28%	304/421 72%	414/850 49%	436/850 51%	16/53 30%	37/53 70%
Total	406/2,019 20%	1613/2,019 80%	957/2,129 45%	1172/2,129 55%	46/235 20%	189/235 80%

*Note: 15 registrants were unable to be classified into an SES group. Proportion of patients who received radiotherapy alone within 90 days of diagnosis, stratified by SES group and institution type (private/public/other unknown). This is calculated as the time between diagnosis and commencement of radiation (external beam or brachytherapy). Australian patients only.*

**Table S33: Proportion of registrants receiving RT+ADT within 90 days of diagnosis by SES group and treating institute (2020–2022)**

	Public		Private		Institute type Other or Unknown	
	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days	Greater than 90 days	Less than or equal to 90 days
SES1	164/691 24%	527/691 76%	44/270 16%	226/270 84%	5/41 12%	36/41 88%
SES2	139/584 29%	445/584 76%	43/326 13%	283/326 87%	6/46 13%	40/46 87%
SES3	160/708 23%	548/708 77%	44/404 11%	360/404 89%	NC	49/50 98%
SES4	120/524 23%	404/524 77%	39/517 7.5%	478/517 92%	NC	47/51 62%
SES5	106/533 20%	427/533 80%	51/589 8.6%	538/589 91%	5/71 7.0%	66/71 93%
Total	689/3,040 23%	2351/3,040 77%	221/2,106 10%	1885/2,106 90%	21/259 8.1%	238/259 92%

Note: 18 registrants were unable to be classified into an SES group. Proportion of patients who received radiotherapy with ADT within 90 days of diagnosis, stratified by SES group and institution type (private/public/other unknown). This is calculated as the time between diagnosis and the commencement of radiation (external beam or brachytherapy) or first ADT administration, whichever came first.

**Table S34: Proportion of registrants receiving surgery by surgical approach and diagnosis year (2020–2022)**

Surgical approach by diagnosis year	Robotic	Open	Laparoscopic	Total
2020	4,169	1,536	255	5,960
	70%	26%	4.3%	
2021	4,534	1,259	191	5,984
	76%	21%	3.2%	
2022	4,772	1,089	176	6,037
	79%	18%	2.9%	
Total	13,475	3,884	622	17,981
	75%	22%	3.5%	

Note: Dropped cases where surgical approach was unknown, open conversions from robotic/laparoscopic, or surgical approach was other unspecified. For 2020, 11 were conversion to open. For 2021, 18 were conversion to open. For 2022, 6 were conversions to open.

**Table S35: Proportion of registrants receiving surgery by surgical approach and treating institute (2020–2022)**

	Public	Private	Institute type Other or Unknown	Total
Robotic	1,596/13,475 12%	11,720/13,475 87%	159/13,475 1.2%	13,475/13,475 100%
Open	2,683/3,884 69%	1,197/3,884 31%	NC	3,884/3,884 100%
Lap	350/622 56%	272/622 44%	NC	622/622 100%
Conversion/Other/Unknown	181/448 40%	244/448 54%	23/448 5.1%	448/448 100%
Total	4,810/18,429 26%	13,433/18,429 73%	186/18,429 1.0%	18,429/18,429 100%

NC, not calculated due to low numbers (n<5).

**Table S36: Proportion of registrants receiving surgery by surgical approach and SES group (2020–2022)**

	Robotic	Open	Laparoscopic
SES1	1,389/1,893 73%	434/1,893 23%	70/1,893 3.7%
SES2	1,694/2,206 77%	439/2,206 20%	73/2,206 3.3%
SES3	1,996/2,570 78%	464/2,570 18%	110/2,570 4.3%
SES4	2,702/3,175 85.10%	399/3,175 13%	74/3,175 2.3%
SES5	4,541/4,995 91%	402/4,995 8.0%	52/4,995 1.0%
<b>Total</b>	12,322/14,839 83%	2,138/14,839 14%	379/14,839 2.6%

Note: 48 registrants were unable to be classified into an SES group

**Table S37: Proportion of registrants receiving surgery by diagnosing and treating institute in Australia and New Zealand (2020–2022)**

Diagnosing Institute Type	Surgical Institute Type			Total (excluding other/unknown)
	Public	Private	Institute type Other or Unknown	
Public (N=4,689)	3,719 79%	956 20%	14 0.30%	4,675
Private (N=13,080)	858 7%	12,093 93%	129 0.99%	12,951
Other or Unknown (N=163)	36 23%	124 76%	NC NC	160
<b>Total (N=17,932)</b>	4,613 26%	13,173 74%	146 0.8%	17,786

Note: Cross over between private and public institutions between diagnosis and surgical treatment, percentages are per row. NC, not calculated due to low numbers (n<5).

**Table S38: Proportion of registrants receiving surgery by diagnosing and treating institute in Australia (2020–2022)**

Diagnosing Institute Type	Surgical Institute Type			Total (excluding other/unknown)
	Public	Private	Institute type Other or Unknown	
Public (N=2,676)	2,028 76%	637 24%	11 0.41%	2,665
Private (N=12,001)	801 7%	11,071 93%	129 1.0%	11,872
Other or Unknown (N=163)	36 22%	124 76%	NC NC	160
<b>Total (N=14,840)</b>	2,865 18%	11,832 80%	143 0.9%	14,697

Note: Cross over between private and public institutions between diagnosis and surgical treatment, percentages are per row. NC, not calculated due to low numbers (n<5).

**Table S39: Proportion of registrants receiving surgery by diagnosing and treating institute in New Zealand (2020–2022)**

Diagnosing Institute Type	Surgical Institute Type			
	Public	Private	Institute type Other or Unknown	Total (excluding other/unknown)
Public (N=2,013)	1,691	319	NC	2,010
	84%	16%	NC	
Private (N=1,079)	57	1,022	NC	1,079
	5%	95%	NC	
Other or Unknown	NC	NC	NC	NC
	NC	NC	NC	
Total (N=3,092)	1,748	1,341	NC	3,089
	57%	43%	NC	

Note: Cross over between private and public institutions between diagnosis and surgical treatment, percentages are per row. NC, not calculated due to low numbers (n<5).

**Table S40: Risk-adjusted model of registrants who had positive surgical margins, by surgical approach and treating institute type (2020–2022)**

	pT2 (n=9,226)			pT3/4 (n=8,496)		
	Public	Private	Total	Public	Private	Total
Robotic	17.57% (15.59-19.55%)	12.57% (11.81-13.34%)	13.95% (13.08-14.82%)	45.24% (42.05-48.43%)	35.91% (34.67-37.15%)	38.2% (36.94-39.47%)
Open	18.25% (16.67-19.83%)	13.31% (11.60-15.01%)	14.67% (13.31-16.03%)	46.37% (43.79-48.96%)	37.40% (34.11-40.69%)	39.60% (36.99-42.21%)
Lap	14.55% (11.32-17.77%)	15.28% (11.53-19.03%)	15.08% (12.19-17.97%)	39.81% (33.69-45.95%)	41.2% (34.31-48.08%)	40.86% (35.41-46.31%)
Total	17.62% (16.11-19.12%)	12.88% (12.09-13.67%)	14.57% (13.83-15.32%)	45.31% (42.82-47.81%)	36.41% (35.18-37.64%)	37.39% (36.33-38.45%)

Note: Predicted rates of positive surgical margins for robotic, open, laparoscopic and institute type (public or private). Presented as predicted percentage with 95% confidence interval.

**Table S41: Proportion of men receiving hypofractionation RT over time (2020–2022)**

	Conventional	Hypofractionation	TOTAL
2020	946	2,259	3,205
	30%	70%	
2021	867	2,666	3,533
	25%	75%	
2022	672	3,161	3,833
	18%	82%	
Total	2,485	8,086	10,571
	24%	76%	

Note: Only patients who had a known radiation dose and number of fractions were included in this Table, as both are needed to determine if a course of treatment was hypofractionated.

**Table S42: Proportion of registrants receiving EBRT with curative intent (received minimum EQD2 of 74 Gy) over time (2020–2022)**

	≥ EQD2 of 74Gy	< EQD2 of 74Gy	TOTAL
<b>2020</b>	2,954	301	3,255
	<b>91%</b>	<b>9.3%</b>	
<b>2021</b>	3,238	334	3,572
	<b>91%</b>	<b>9.4%</b>	
<b>2022</b>	3,567	292	3,859
	<b>92%</b>	<b>7.6%</b>	
<b>Total</b>	9,759	927	10,686
	<b>91%</b>	<b>8.7%</b>	

**Table S43: Proportion of registrants receiving EBRT with curative intent (received minimum EQD2 of 74 Gy) by NCCN**

	≥ EQD2 of 74Gy	< EQD2 of 74Gy	TOTAL
<b>Low Risk</b>	131	NC	135
	<b>97%</b>	<b>NC</b>	
<b>Intermediate Risk</b>	3,923	206	4,129
	<b>95%</b>	<b>4.9%</b>	
<b>High Risk</b>	3,817	358	4,175
	<b>91%</b>	<b>8.6%</b>	
<b>Regional Disease</b>	797	116	913
	<b>87%</b>	<b>12.7%</b>	
<b>Missing</b>	694	57	751
	<b>92%</b>	<b>7.6%</b>	

*Note: This Table doesn't include registrants with metastatic disease. Total known includes low, intermediate, high/very high, and regional disease. Missing refers to patients where an NCCN classification could not be assigned.*

Year	NSW	VIC	QLD	SA	TAS	NT	ACT	NZ	AUS	ANZ
2020	1,503/ 4,350	2,149/ 4,211	1,830/ 3,395	530/ 1,294	270/ 356	21/ 80	330/ 405	1,628/ 3,156	6,633/ 14,091	8,261/ 17,247
	<b>35%</b>	<b>51%</b>	<b>54%</b>	<b>41%</b>	<b>76%</b>	<b>26%</b>	<b>81%</b>	<b>52%</b>	<b>47%</b>	<b>48%</b>
2021	1,676/ 5,208	2,643/ 4,803	1,345/ 2,972	596/ 1,411	373/ 513	28/ 97	325/ 459	1,589/ 3,417	6,986/ 15,463	8,575/ 18,880
	<b>32%</b>	<b>55%</b>	<b>45%</b>	<b>42%</b>	<b>73%</b>	<b>29%</b>	<b>71%</b>	<b>47%</b>	<b>45%</b>	<b>45%</b>
2022	2,153/ 6,174	2,057/ 4,867	1,648/ 3,366	415/ 1,174	507/ 761	44/ 114	343/ 495	1,872/ 3,599	7,167/ 16,951	9,039/ 20,550
	<b>35%</b>	<b>42%</b>	<b>49%</b>	<b>35%</b>	<b>67%</b>	<b>39%</b>	<b>69%</b>	<b>52%</b>	<b>42%</b>	<b>44%</b>
Total	5,332/ 15,732	6,849/ 13,881	4,823/ 9,733	1,541/ 3,879	1,150/ 1,630	93/ 291	998/ 1,359	5,089/ 10,172	20,786/ 46,505	25,875/ 56,677
	<b>34%</b>	<b>49%</b>	<b>50%</b>	<b>40%</b>	<b>71%</b>	<b>32%</b>	<b>73%</b>	<b>50%</b>	<b>45%</b>	<b>46%</b>

Year	NT	SA	NZ	Total
2020	14/80	521/1,294	1,415/3,156	1,950/4,530
	<b>18%</b>	<b>40%</b>	<b>45%</b>	<b>43.05%</b>
2021	22/97	553/1,411	1,246/3,417	1,821/4,925
	<b>23%</b>	<b>39%</b>	<b>37%</b>	<b>37%</b>
2022	17/114	387/1,174	1,011/3,599	1,415/4,887
	<b>15%</b>	<b>33%</b>	<b>28%</b>	<b>29%</b>
Total	53/291	1461/3879	3,672/10,172	5,186/14,342
	<b>18%</b>	<b>38%</b>	<b>36%</b>	<b>36%</b>

*Note: Answered at least one question divided by all patients included.*

<b>Table S46: Mode of PROMs administration</b>			
<b>Baseline</b>			
	<b>Phone</b>	<b>Email</b>	<b>Mail</b>
<b>2020</b>	-	152/2,780	2,628/2,780
		<b>5.5%</b>	<b>95%</b>
<b>2021</b>	-	119/2,882	2,763/2,882
		<b>4.1%</b>	<b>96%</b>
<b>2022</b>	-	74/2,114	2,040/2,114
		<b>3.5%</b>	<b>97%</b>
<b>Total</b>	-	345/7,776	7,431/7,776
		<b>4.4%</b>	<b>96%</b>
<b>12-month PROMs</b>			
	<b>Phone</b>	<b>Email</b>	<b>Mail</b>
<b>2020</b>	1,201/8,745	1,942/8,745	5,602/8,745
	<b>21%</b>	<b>22%</b>	<b>64%</b>
<b>2021</b>	1,328/9,465	1,953/9,465	6,184/9,465
	<b>22%</b>	<b>21%</b>	<b>65%</b>
<b>2022</b>	945/9,803	1,939/9,803	6,919/9,803
	<b>14%</b>	<b>20%</b>	<b>70%</b>
<b>Total</b>	3,474/28,013	5,834/28,013	18,705/28,013
	<b>19%</b>	<b>21%</b>	<b>67%</b>
<i>Note: Phone was dropped from baseline Table as there were only 3 people who responded by phone across the 3-year period. Table includes NZ, SA, and NT.</i>			

Table S47: PROMs responses to individual questions by management group, in men with low-risk disease

LOW RISK									
PROM	Surgery	RT-ADT	RT+ADT	ADT +/-Chemo*	AS	WW	Other treatment	Treatment information missing	Overall Total
<b>Urinary</b>									
Urinary Bother	39/493 7.91%	8/121 6.61%	NC	NC	252/2,856 8.82%	7/70 10.00%	NC	8/71 11.27%	317/3,653 8.68%
One or more pads per day	134/497 26.96%	6/121 4.96%	NC	NC	92/2,886 3.19%	5/69 7.25%	NC	8/71 11.27%	247/3,686 6.70%
Leaked Urine	85/497 17.10%	9/121 7.44%	NC	NC	190/2,884 6.59%	NC	NC	10/71 14.08%	303/3,685 8.22%
Urinary Continence summary score (median-IQR)	85.5 (64.75-100) N=498	100 (79.25-100) N=122	92.75 (80.67-100) N=18	88.63 (66.75-100) N=14	100 (85.5-100) N=2,891	100 (75-100) N=71	83.38 (73-100) N=10	100 (73-100) N=72	100 (79.25-100) N=3,696
Urinary obstruction summary score (median-IQR)	93.75 (87.5-100) N=495	87.5 (75-93.75) N=122	87.5 (75-93.75) N=17	90.63 (87.5-100) N=14	87.5 (75-100) N=2,871	93.75 (81.25-100) N=69	93.75 (81.25-100) N=10	93.75 (81.25-100) N=70	93.75 (81.25-100) N=3,668
<b>Bowel</b>									
Bowel Bother	11/496 2.22%	9/121 7.44%	NC	NC	78/2,865 2.72%	NC	NC	NC	103/3,665 2.81%
Loss of Bowel Control	7/492 1.42%	NC	NC	NC	41/2,850 1.44%	NC	NC	NC	56/3,638 1.54%
Bowel function summary score (median-IQR)	100 (95.83-100) N=497	95.83 (83.33-100) N=121	93.33 (87.5-100) N=18	95.83 (87.5-100) N=14	100 (91.67-100) N=2,880	100 (87.5-100) N=71	95.83 (91.67-100) N=10	100 (91.67-100) N=73	100 (91.67-100) N=3,684
<b>Sexual</b>									
Sexual Bother	232/492 47.15%	44/181 37.29%	9/18 50.00%	NC	652/2,798 23.30%	14/65 21.54%		17/68 25.00%	974/3,583 27.18%

<b>Ability to have an erection</b>	160/492 <b>32.52%</b>	49/120 <b>40.83%</b>	NC	NC	1,852/2,802 <b>66.10%</b>	28/64 <b>43.75%</b>	NC	38/71 <b>53.52%</b>	2,136/3,591 <b>59.48%</b>
<b>Quality of erection</b>	92/489 <b>18.81%</b>	36/119 <b>30.25%</b>	<b>NC</b>	NC	1,388/2,782 <b>49.89%</b>	18/66 <b>27.27%</b>	NC	27/70 <b>38.57%</b>	1,568/3,568 <b>43.95%</b>
<b>Ability to function sexually</b>	152/488 <b>31.15%</b>	48/119 <b>40.34%</b>	NC	NC	1,813/2,784 <b>65.12%</b>	28/65 <b>43.08%</b>	NC	36/68 <b>52.94%</b>	2,085/3,565 <b>58.49%</b>
<b>Interested in sex</b>	216/492 <b>43.90%</b>	39/119 <b>32.77%</b>	NC	NC	1,311/2,827 <b>46.37%</b>	20/66 <b>30.030%</b>	NC	28/71 <b>39.44%</b>	1,622/3,614 <b>44.88%</b>
<b>Use of sexual aids</b>	306/495 <b>61.82%</b>	42/118 <b>35.59%</b>	NC	NC	731/2,841 <b>25.73%</b>	15/66 <b>22.73%</b>	NC	22/71 <b>30.99%</b>	1,126/3,630 <b>31.02%</b>
<b>Sexual function summary score (median-IQR)</b>	<b>25</b> (12.5-57) N=494	<b>34.67</b> (16.67-62.5) N=120	<b>15.25</b> (5.5-22.17) N=18	<b>20.83</b> (16.67-45.83) N=14	<b>65.33</b> (36.17-87.5) N=2,829	<b>34.67</b> (16.67-66.67) N=67	<b>54.17</b> (16.67-62.5) N=10	<b>58.33</b> (16.67-83.33) N=71	<b>57</b> (26.33-83.33) N=3,623
<b>Hormonal</b>									
<b>Feeling depressed</b>	52/490 <b>10.60%</b>	8/120 <b>6.67%</b>	NC	NC	204/2,823 <b>7.23%</b>	NC	NC	6/70 <b>8.57%</b>	276/3,607 <b>7.65%</b>
<b>Lack of energy</b>	63/495 <b>12.73%</b>	25/120 <b>20.83%</b>	5/18 <b>27.78%</b>	5/14 <b>35.71%</b>	292/2,837 <b>10.29%</b>	8/65 <b>12.31%</b>	NC	14/70 <b>20.00%</b>	412/3,629 <b>11.35%</b>
<b>Hormonal function summary score (median-IQR)</b>	<b>95</b> (80-100) N=496	<b>90</b> (80-100) N=121	<b>75</b> (55-85) N=18	<b>85</b> (80-95) N=14	<b>95</b> (85-100) N=2,854	<b>95</b> (80-100) N=66	<b>92.5</b> (90-95) N=10	<b>95</b> (85-100) N=70	<b>95</b> (85-100) N=3,649
*For the 14 patients in the ADT-/±Chemotherapy column, none were receiving chemotherapy, all were receiving ADT. NC, not calculated due to low numbers (n<5).									

**Table S48: PROMs responses to individual questions by management group, in men with intermediate-risk disease**

INTERMEDIATE RISK									
PROM	Surgery	RT-ADT	RT+ADT	ADT +/-Chemo*	AS	WW	Other treatment	Treatment information missing	Total
<b>Urinary</b>									
<b>Urinary Bother</b>	548/6,228 <b>8.80%</b>	152/1,593 <b>9.54%</b>	120/1,016 <b>11.81%</b>	19/104 <b>18.27%</b>	101/1,281 <b>7.88%</b>	18/180 <b>10.00%</b>	5/45 <b>4.44%</b>	18/221 <b>8.14%</b>	978/10,668 <b>9.17%</b>
<b>One or more pads per day</b>	1,783/6,257 <b>28.50%</b>	100/1,609 <b>6.22%</b>	61/1,034 <b>5.90%</b>	18/106 <b>16.98%</b>	60/1,289 <b>4.65%</b>	13/186 <b>6.99%</b>	NC	22/225 <b>9.78%</b>	2,060/10,751 <b>19.16%</b>
<b>Leaked Urine</b>	1,171/6,260 <b>18.71%</b>	134/1,610 <b>8.32%</b>	96/1,032 <b>9.30%</b>	19/107 <b>17.76%</b>	106/1,290 <b>8.22%</b>	17/184 <b>9.24%</b>	NC	22/226 <b>9.73%</b>	1,566/10,754 <b>14.56%</b>
<b>Urinary Continence summary score (median-IQR)</b>	<b>85.5</b> (60.5-100) N=6,272	<b>100</b> (79.25-100) N=1,614	<b>100</b> (79.25-100) N=1,037	<b>87.5</b> (66.75-100) N=109	<b>100</b> (83.33-100) N=1,293	<b>93.75</b> (73-100) N=187	<b>100</b> (79.25-100) N=45	<b>100</b> (79.25-100) N=226	<b>91.75</b> (66.75-100) N=10,783
<b>Urinary obstruction summary score (median-IQR)</b>	<b>91.75</b> (66.75-100) N=6,212	<b>87.5</b> (75-100) n=1,590	<b>87.5</b> (81.25-100) N=1,023	<b>87.5</b> (75-100) N=109	<b>93.75</b> (81.25-100) N=1,285	<b>87.5</b> (81.25-100) N=180	<b>93.75</b> (87.5-100) N=45	<b>93.75</b> (81.25-100) N=224	<b>93.75</b> (87.5-100) N=10,668
<b>Bowel</b>									
<b>Bowel Bother</b>	152/6,235 <b>2.44%</b>	104/1,589 <b>6.54%</b>	81/1,015 <b>7.98%</b>	14/105 <b>13.33%</b>	41/1,280 <b>3.20%</b>	9/186 <b>4.84%</b>	NC	8/225 <b>3.56%</b>	411/10,680 <b>3.85%</b>
<b>Loss of Bowel Control</b>	55/6,198 <b>0.89%</b>	68/1,558 <b>4.36%</b>	41/1,000 <b>4.1%</b>	8/107 <b>7.48%</b>	21/1,266 <b>1.66%</b>	NC	NC	NC	199/10,568 <b>1.88%</b>
<b>Bowel function summary score (median-IQR)</b>	<b>100</b> (95.83-100) N=6,268	<b>95.83</b> (83.33-100) N=1,609	<b>95.83</b> (83.33-100) N=1,030	<b>100</b> (87.5-100) N=109	<b>100</b> (91.67-100) N=1,291	<b>100</b> (87.5-100) N=186	<b>100</b> (91.67-100) N=45	<b>100</b> (61.67-100) N=226	<b>100</b> (91.67-100) N=10,764
<b>Sexual</b>									
<b>Sexual Bother</b>	2,808/6,153 <b>45.64%</b>	519/1,532 <b>33.88%</b>	396/990 <b>40.00%</b>	26/101 <b>25.74%</b>	293/1,226 <b>25.74%</b>	55/162 <b>33.95%</b>	14/44 <b>31.82%</b>	73/215 <b>33.95%</b>	4,184/10,423 <b>40.14%</b>

<b>Ability to have an erection</b>	1,527/6,189 <b>24.67%</b>	604/1,556 <b>38.82%</b>	206/995 <b>20.70%</b>	12/101 <b>11.88%</b>	727/1,242 <b>58.53%</b>	58/170 <b>34.12%</b>	19/45 <b>42.22%</b>	98/217 <b>45.16%</b>	3,251/10,515 <b>30.92%</b>
<b>Quality of erection</b>	832/6,139 <b>13.55%</b>	402/1,534 <b>26.21%</b>	123/985 <b>12.49%</b>	6/102 <b>5.88%</b>	503/1,225 <b>41.06%</b>	31/167 <b>18.56%</b>	12/43 <b>27.91%</b>	73/216 <b>33.80%</b>	1,982/10,411 <b>19.04%</b>
<b>Ability to function sexually</b>	1,637/6,148 <b>6.63%</b>	585/1,532 <b>38.19%</b>	194/987 <b>19.66%</b>	9/101 <b>8.91%</b>	689/1,216 <b>56.66%</b>	50/164 <b>30.49%</b>	17/44 <b>38.64%</b>	101/216 <b>46.76%</b>	3,282/10,408 <b>31.53%</b>
<b>Interested in sex</b>	2,480/6,174 <b>40.17%</b>	525/1,566 <b>33.52%</b>	217/1,000 <b>21.70%</b>	8/105 <b>7.62%</b>	541/1,238 <b>43.70%</b>	49/169 <b>28.99%</b>	20/42 <b>47.62%</b>	85/222 <b>38.29%</b>	3,925/10,516 <b>37.32%</b>
<b>Use of sexual aids</b>	3,977/6,210 <b>64.04%</b>	461/1,579 <b>29.20%</b>	188/1,009 <b>18.63%</b>	13/107 <b>12.15%</b>	344/1,255 <b>27.41%</b>	42/171 <b>24.56%</b>	16/45 <b>35.56%</b>	79/221 <b>35.75%</b>	5,120/10,597 <b>48.32%</b>
<b>Sexual function summary score (median-IQR)</b>	<b>20.83</b> (9.67-48.67) N=6216	<b>34.67</b> (16.67-62.5) N=1572	<b>16.67</b> (8.33-36.83) N=1008	<b>16.67</b> (8.33-25) N=106	<b>57</b> (25-83.33) N=1255	<b>26.33</b> (13.83-54.92) N=172	<b>37.50</b> (16.67-75) N=45	<b>40.33</b> (16.67-70.83) M=218	<b>25</b> (12.5-57) N=10592
<b>Hormonal</b>									
<b>Feeling depressed</b>	580/6,160 <b>9.42%</b>	126/1,550 <b>8.13%</b>	86/997 <b>8.63%</b>	11/104 <b>10.58%</b>	74/1,251 <b>5.92%</b>	12/174 <b>6.90%</b>	NC	17/221 <b>7.69%</b>	909/10,500 <b>8.66%</b>
<b>Lack of energy</b>	671/6,178 <b>10.86%</b>	263/1,564 <b>16.82%</b>	249/1,010 <b>24.65%</b>	31/104 <b>29.81%</b>	160/1,259 <b>12.71%</b>	34/176 <b>19.32%</b>	11/45 <b>24.44%</b>	33/223 <b>14.80%</b>	1,452/10,559 <b>13.75%</b>
<b>Hormonal function summary score (median-IQR)</b>	<b>95</b> (85-100) N=6,208	<b>90</b> (80-100) N=1,577	<b>80</b> (65-95) N=1,023	<b>80</b> (65-95) N=105	<b>95</b> (85-100) N=1,268	<b>95</b> (85-100) N=177	<b>95</b> (75-100) N=45	<b>95</b> (80-100) N=224	<b>95</b> (80-100) N=10,672
*For the 109 patients in the ADT-/+Chemo column, none were receiving chemotherapy, all were receiving ADT. NC, not calculated due to low numbers (n<5).									

**Table S49: PROMs responses to individual questions by management group, in men with high-risk disease**

<b>HIGH RISK</b>									
	<b>Surgery</b>	<b>RT-ADT</b>	<b>RT+ADT</b>	<b>ADT +/-Chemo*</b>	<b>AS</b>	<b>WW</b>	<b>Other treatment</b>	<b>Treatment information missing</b>	<b>Total</b>
<b>Urinary</b>									
<b>Urinary Bother</b>	351/2,928 <b>11.9%</b>	58/420 <b>13.81%</b>	276/1,888 <b>14.62%</b>	56/372 <b>15.05%</b>	8/112 <b>7.14%</b>	17/109 <b>15.60%</b>	NC	19/185 <b>10.27%</b>	789/6,043 <b>13.06%</b>
<b>One or more pads per day</b>	1,081/2,940 <b>36.77%</b>	36/422 <b>8.53%</b>	200/1,897 <b>10.54%</b>	52/378 <b>13.76%</b>	7/110 <b>6.36%</b>	14/113 <b>12.39%</b>	NC	32/187 <b>17.11%</b>	1,426/6,077 <b>23.47%</b>
<b>Leaked Urine</b>	757/2,943 <b>25.72%</b>	51/420 <b>12.14%</b>	232/1,898 <b>12.22%</b>	60/377 <b>15.92%</b>	13/111 <b>11.71%</b>	16/111 <b>14.41%</b>	NC	29/189 <b>15.34%</b>	1,161/6,079 <b>19.10%</b>
<b>Urinary Continence summary score (median-IQR)</b>	<b>77.25</b> (52.25-100) N=2,950	<b>100</b> (73-100) N=425	<b>93.75</b> (73-100) N=1,906	<b>93.75</b> (66.75-100) N=379	<b>100</b> (79.25-100) N=112	<b>93.75</b> (73-100) N=113	<b>100</b> (75-100) N=30	<b>100</b> (66.75-100) N=190	<b>85.5</b> (60.5-100) N=6,105
<b>Urinary obstruction summary score (median-IQR)</b>	<b>93.75</b> (87.5-100) N=2,905	<b>87.5</b> (75-100) N=418	<b>87.5</b> (75-100) N=1,874	<b>93.75</b> (75-100) N=370	<b>87.5</b> (81.25-100) N=111	<b>87.5</b> (68.75-100) N=112	<b>87.5</b> (75-100) N=30	<b>93.75</b> (81.25-100) N=182	<b>93.75</b> (81.25-100) N=6,002
<b>Bowel</b>									
<b>Bowel Bother</b>	117/2,929 <b>3.99%</b>	42/422 <b>9.95%</b>	188/1,867 <b>10.07%</b>	31/371 <b>8.36%</b>	8/112 <b>7.14%</b>	10/111 <b>9.01%</b>	NC	10/191 <b>5.24%</b>	409/6,031 <b>6.78%</b>
<b>Loss of Bowel Control</b>	39/2,892 <b>1.35%</b>	24/404 <b>5.94%</b>	103/1,819 <b>5.66%</b>	11/350 <b>3.14%</b>	NC	NC	NC	NC	189/5893 <b>3.21%</b>
<b>Bowel function summary score (median-IQR)</b>	<b>100</b> (91.67-100) N=2,941	<b>95.83</b> (79.17-100) N=426	<b>91.67</b> (79.17-100) N=1,898	<b>95.83</b> (86.25-100) N=380	<b>100</b> (85.42-100) N=112	<b>95.83</b> (83.33-100) N=114	<b>91.66</b> (87.5-100) N=29	<b>95.83</b> (87.5-100) N=193	<b>100</b> (87.5-100) N=6,093
<b>Sexual</b>									
<b>Sexual Bother</b>	1,316/2,873 <b>45.81%</b>	150/393 <b>38.17%</b>	668/1,774 <b>37.66%</b>	104/341 <b>30.50%</b>	23/99 <b>23.23%</b>	26/102 <b>25.49%</b>	9/29 <b>31.03%</b>	61/158 <b>38.61%</b>	2,357/5,769 <b>40.86%</b>

<b>Ability to have an erection</b>	375/2,897 <b>12.94%</b>	81/400 <b>20.25%</b>	133/1,814 <b>7.33%</b>	25/357 <b>7.00%</b>	43/100 <b>43.00%</b>	25/107 <b>23.36%</b>	NC	21/161 <b>13.04%</b>	707/5,865 <b>12.05%</b>
<b>Quality of erection</b>	192/2,882 <b>6.66%</b>	38/402 <b>9.45%</b>	67/1,802 <b>3.72%</b>	11/353 <b>3.12%</b>	29/98 <b>29.59%</b>	10/104 <b>9.62%</b>	NC	13/160 <b>8.12%</b>	362/5,830 <b>6.21%</b>
<b>Ability to function sexually</b>	433//2,876 <b>15.06%</b>	73/392 <b>18.62%</b>	109/1,770 <b>6.16%</b>	14/344 <b>4.07%</b>	40/99 <b>40.40%</b>	18/104 <b>17.31%</b>	NC	14/157 <b>8.92%</b>	705/5,771 <b>12.22%</b>
<b>Interested in sex</b>	943/2,896 <b>32.56%</b>	83/406 <b>20.44%</b>	165/1,839 <b>8.97%</b>	23/360 <b>6.39%</b>	28/101 <b>27.72%</b>	20/108 <b>18.52%</b>	NC	19/182 <b>10.44%</b>	1,283/5,922 <b>21.66%</b>
<b>Use of sexual aids</b>	1,509/2,913 <b>51.80%</b>	56/399 <b>14.04%</b>	215/1,851 <b>11.62%</b>	28/359 <b>7.80%</b>	20/108 <b>18.52%</b>	11/109 <b>10.09%</b>	7/30 <b>23.33%</b>	23/182 <b>12.64%</b>	1,869/5,951 <b>31.41%</b>
<b>Sexual function summary score (median-IQR)</b>	<b>16.67</b> (5.5-27.83) N=2910	<b>16.67</b> (8.33-36.17) N=412	<b>16.67</b> (4.17-16.67) N=1835	<b>16.67</b> (4.17-16.67) N=364	<b>40.33</b> (16.67-75) N=103	<b>16.67</b> (9.67-38.83) N=109	<b>16.67</b> (8.33-30.5) N=29	<b>16.67</b> (4.17-25) N=167	<b>16.67</b> (4.17-25) N=5929
<b>Hormonal</b>									
<b>Feeling depressed</b>	307/2,886 <b>10.64%</b>	45/402 <b>11.19%</b>	243/1,814 <b>13.40%</b>	41/358 <b>13.40%</b>	8/110 <b>7.27%</b>	10/107 <b>9.35%</b>	5/30 <b>16.67%</b>	20/180 <b>11.11%</b>	679/5,887 <b>11.53%</b>
<b>Lack of energy</b>	416/2,897 <b>14.36%</b>	107/407 <b>26.29%</b>	625/1,845 <b>33.88%</b>	131/366 <b>35.79%</b>	15/109 <b>13.76%</b>	21/106 <b>19.81%</b>	9/29 <b>31.03%</b>	57/184 <b>30.98%</b>	1,381/5,943 <b>23.24%</b>
<b>Hormonal function summary score (median-IQR)</b>	<b>90</b> (80-100) N=2,916	<b>85</b> (70-95) N=415	<b>75</b> (55-90) N=1,877	<b>75</b> (60-90) N=373	<b>95</b> (85-100) N=111	<b>90</b> (80-100) N=110	<b>75</b> (60-90) N=30	<b>80</b> (65-95) N=188	<b>85</b> (70-100) N=6,020
*For the 386 people in the ADT+/-Chemo column, 11 were receiving ADT+Chemotherapy, 373 were receiving only ADT, and 2 were receiving chemotherapy only. NC, not calculated due to low numbers (n<5).									

**Table S50: PROMs responses to individual questions by management group, in men with regional disease**

REGIONAL									
	Surgery	RT-ADT	RT+ADT	ADT +/-Chemo*	AS	WW	Other treatment	Treatment information missing	Total
<b>Urinary</b>									
<b>Urinary Bother</b>	18/149 <b>12.08%</b>	6/38 <b>15.79%</b>	61/469 <b>13.01%</b>	21/156 <b>13.46%</b>	NC		NC	NC	111/833 <b>13.33%</b>
<b>One or more pads per day</b>	64/150 <b>42.67%</b>	6/37 <b>16.22%</b>	51/476 <b>10.71%</b>	14/155 <b>9.03%</b>	NC		NC	NC	138/838 <b>16.47%</b>
<b>Leaked Urine</b>	45/150 <b>30.00%</b>	9/37 <b>24.32%</b>	55/476 <b>11.55%</b>	11/155 <b>7.10%</b>	NC	NC	NC	NC	122/838 <b>14.56%</b>
<b>Urinary Continence summary score (median-IQR)</b>	<b>74</b> (52.25-100) N=150	<b>92.75</b> (60.5-100) N=38	<b>100</b> (67.75-100) N=476	<b>100</b> (85.5-100) N=157	NC	<b>73</b> (54.25-91.75) N=5	<b>66.75</b> (66.75-100) N=5	<b>100</b> (75-100) N=10	<b>93.75</b> (66.75-100) N=842
<b>Urinary obstruction summary score (median-IQR)</b>	<b>93.75</b> (87.5-100) N=146	<b>81.25</b> (75-93.75) N=38	<b>87.5</b> (75-100) N=468	<b>87.5</b> (75-100) N=154		<b>87.5</b> (68.75-100) N=5	<b>87.5</b> (81.25-93.75) N=5	<b>93.75</b> (87.5-100) N=10	<b>87.5</b> (75-100) N=827
<b>Bowel</b>									
<b>Bowel Bother</b>	12/149 <b>8.05%</b>	NC	54/471 <b>11.46%</b>	5/151 <b>3.31%</b>	NC	NC	NC	NC	76/829 <b>9.17%</b>
<b>Loss of Bowel Control</b>	NC	5/37 <b>13.51%</b>	28/455 <b>6.15%</b>	NC	NC	NC	NC	NC	41/806 <b>5.09%</b>
<b>Bowel function summary score (median-IQR)</b>	<b>100</b> (83.33-100) N=149	<b>90.83</b> (83.33-100) N=38	<b>91.67</b> (75-100) N=475	<b>100</b> (87.5-100) N=153	NC	<b>66.67</b> (62.5-91.67) N=5	<b>95.83</b> (91.67-100) N=5	<b>91.67</b> (87.5-100) N=10	<b>95.83</b> (79.17-100) N=836
<b>Sexual</b>									
<b>Sexual Bother</b>	80/144 <b>55.56%</b>	16/35 <b>45.71%</b>	180/448 <b>40.18%</b>	45/142 <b>31.69%</b>	NC	NC	NC	NC	327/786 <b>41.60%</b>

<b>Ability to have an erection</b>	11/144 <b>7.64%</b>	NC	26/448 <b>5.80%</b>	6/148 <b>4.05%</b>	NC	NC	NC	NC	46/794 <b>5.79%</b>
<b>Quality of erection</b>	NC	NC	6/447 <b>1.34%</b>	5/146 <b>3.42%</b>	NC	NC	NC	NC	16/791 <b>2.02%</b>
<b>Ability to function sexually</b>	12/145 <b>8.28%</b>	NC	11/446 <b>2.47%</b>	7/141 <b>4.96%</b>	NC	NC	NC	NC	32/782 <b>4.09%</b>
<b>Interested in sex</b>	40/145 <b>27.59%</b>	NC	30/464 <b>6.47%</b>	14/146 <b>9.59%</b>	NC	NC	NC	NC	88/809 <b>10.88%</b>
<b>Use of sexual aids</b>	70/147 <b>47.62%</b>	8/37 <b>21.62%</b>	50/464 <b>10.78%</b>	19/148 <b>12.84%</b>	NC	NC	NC	NC	149/814 <b>18.30%</b>
<b>Sexual function summary score (median-IQR)</b>	<b>12.5</b> (0-16.67) N=145	<b>16.67</b> (0-20) N=37	<b>16.67</b> (0-16.67) N=460	<b>16.67</b> (4.17-16.67) N=148	NC	<b>16.67</b> (0-16.67) N=5	NC	<b>10.42</b> (4.17-16.67) N=8	<b>16.67</b> (0-16.67) N=808
<b>Hormonal</b>									
<b>Feeling depressed</b>	22/148 <b>14.86%</b>	7/35 <b>20.00%</b>	74/459 <b>16.12%</b>	17/152 <b>11.18%</b>	NC	NC	NC	NC	121/814 <b>14.86%</b>
<b>Lack of energy</b>	32/146 <b>21.92%</b>	11/36 <b>30.56%</b>	178/465 <b>38.28%</b>	55/150 <b>36.67%</b>	NC	NC	NC	NC	283/817 <b>34.64%</b>
<b>Hormonal function summary score (median-IQR)</b>	<b>80</b> (65-95) N=148	<b>75</b> (55-85) N=38	<b>70</b> (55-85) N=473	<b>75</b> (60-85) N=153	NC	<b>70</b> (70-90) N=5	<b>80</b> (60-95) N=5	<b>85</b> (80-90) N=9	<b>75</b> (55-85) N=832

\*For the 157 patients in the ADT+/-Chemo column, 40 were receiving ADT+Chemotherapy, 116 were receiving ADT only, and 1 was receiving chemotherapy only. NC, not calculated due to low numbers (n<5).

Table S51: PROMs responses to individual questions by management group, in men with metastatic disease

METASTATIC									
PROM	Surgery	RT-ADT	RT+ADT	ADT +/-Chemo*	AS	WW	Other treatment	Treatment information missing	Total
<b>Urinary</b>									
Urinary Bother	8/53 15.09%	NC	63/459 13.73%	105/780 13.46%	NC	NC	NC	NC	181/1,342 13.49%
One or more pads per day	22/53 41.51%	NC	48/463 10.37%	83/789 10.52%	NC	NC	NC	NC	156/1,354 11.52%
Leaked Urine	14/53 26.42%	NC	52/465 11.18%	89/786 11.32%	NC	NC	NC	NC	157/1,353 11.60%
Urinary continence summary score (median-IQR)	79.25 (52.25-100) N=53	91.75 (70.875-100) N=24	100 (73-100) N=468	100 (79.25-100) N=795	91.75 (79.25-100) N=9	87.5 (79.25-100) N=5	85.5 (85.5-100) N=9	NC	100 (75-100) N=1,366
Urinary obstruction summary score (median-IQR)	93.75 (87.5-100) N=53	87.5 (81.25-100) N=24	87.5 (75-100) N=461	93.75 (81.25-100) N=774	81.25 (81.25-93.75) N=9	100 (93.75-100) N=5	93.75 (87.5-100) N=9	NC	93.75 (75-100) N=1,338
<b>Bowel</b>									
Bowel Bother	NC	NC	53/461 11.50%	63/779 8.09%	NC	NC	NC	NC	122/1,343 9.08%
Loss of Bowel Control	NC	NC	19/459 4.14%	21/743 2.83%	NC	NC	NC	NC	44/1,303 3.38%
Bowel function summary score (median-IQR)	100 (91.67-100) N=53	91.67 (81.25-100) N=24	91.67 (79.17-100) N=470	100 (87.5-100) N=792	91.67 (83.33-95.83) N=9	95.83 (91.67-100) N=5	95.83 (83.33-100) N=9	NC	95.83 (93.33-100) N=1,365
<b>Sexual</b>									
Sexual Bother	22/50 44.00%	8/24 33.33%	158/438 36.07%	249/726 34.30%	NC	NC	NC	NC	441/1,255 35.14%

<b>Ability to have an erection</b>	6/50 <b>12.00%</b>	5/24 <b>20.83%</b>	23/446 <b>5.16%</b>	45/738 <b>6.10%</b>	NC	NC	NC	NC	87/1,277 <b>6.81%</b>
<b>Quality of erection</b>	NC	NC	13/439 <b>2.96%</b>	29/731 <b>3.97%</b>	NC	NC	NC	NC	49/1,262 <b>3.88%</b>
<b>Ability to function sexually</b>	6/48 <b>12.50%</b>	NC	25/435 <b>5.75%</b>	33/723 <b>4.56%</b>	5/6 <b>55.56%</b>	NC	NC	NC	72/1,247 <b>5.77%</b>
<b>Interested in sex</b>	14/49 <b>28.57%</b>	NC	23/447 <b>5.15%</b>	38/752 <b>5.05%</b>	NC	NC	NC	NC	82/1,294 <b>6.34%</b>
<b>Use of sexual aids</b>	21/49 <b>42.86%</b>	NC	45/453 <b>9.93%</b>	86/761 <b>11.30%</b>	NC	NC	NC	NC	158/1,310 <b>12.06%</b>
<b>Sexual function summary score (median-IQR)</b>	<b>16.67</b> (4.17-29.17) N=50	<b>16.67</b> (7.83-30.5) N=24	<b>16.67</b> (4.17-16.67) N=452	<b>16.67</b> (0-16.67) N=754	<b>57</b> (22.17-73.67) N=9	NC	<b>22.17</b> (8.33-25) N=5	NC	<b>16.67</b> (4.17-16.67) N=1300
<b>Hormonal</b>									
<b>Feeling depressed</b>	5/49 <b>10.20%</b>	NC	63/458 <b>13.76%</b>	97/754 <b>12.86%</b>	NC	NC	NC	NC	171/1,311 <b>13.04%</b>
<b>Lack of energy</b>	13/48 <b>27.08%</b>	7/24 <b>29.17%</b>	188/465 <b>40.43%</b>	272/769 <b>35.37%</b>	NC	NC	NC	NC	486/1,332 <b>36.49%</b>
<b>Hormonal function summary score (median-IQR)</b>	<b>80.63</b> (60-90) N=50	<b>80</b> (72.5-90) N=24	<b>70</b> (55-85) N=466	<b>75</b> (55-85) N=781	<b>90</b> (85-90) N=9	<b>95</b> (90-95) N=5	<b>80</b> (55-85) N=9	NC	75 (55-85) N=1,347
*For the 799 patients in the ADT-/±Chemo column, 384 were receiving ADT+chemotherapy, 412 were receiving ADT alone, and 3 patients were receiving chemotherapy alone. NC, not calculated due to low numbers (n<5).									

Table S52: PROMs responses to individual questions by men with intermediate-risk disease who have had surgery					
	Urinary Bother	One or more pads per day	Leaked Urine	Sexual Bother	Sexual function summary score
Less than 60	86/1,396 6.16%	295/1,402 21.04%	187/1,406 13.30%	666/1,396 47.71%	40.33 (16.67–66.67) N=1,404
60 to 64	121/1,425 8.49%	370/1,431 25.86%	239/1,432 16.69%	678/1,408 48.15%	25 (12.5–52.83) N=1,418
65 to 69	172/1,811 9.50%	528/1,818 29.04%	355/1,818 19.53%	813/1,788 45.47%	16.67 (8.33–40.33) N=1,807
70 to 74	121/1,203 10.06%	435/1,209 35.98%	289/1,208 23.92%	517/1,171 44.15%	16.67 (6.25–32) N=1,192
Greater than 75	48/393 12.21%	155/397 39.04%	101/396 25.51%	134/390 34.36%	16.67 (8.33–20.83) N=395
Total	548/6,228 8.80%	1,783/6,257 28.50%	1,171/6,260 18.71%	2,808/6,153 45.64%	20.83 (9.67–48.67) N=6,216

Table S53: PROMs responses to individual questions from men with high-risk disease who have had surgery					
	Urinary Bother	One or more pads per day	Leaked Urine	Sexual Bother	Sexual function summary score (median/IQR)
Less than 60	39/369 10.57%	111/374 29.68%	86/374 22.99%	196/366 53.55%	20.83 (8.33–49.33) N=368
60 to 64	40/505 7.92%	152/506 30.04%	101/506 19.96%	259/500 51.80%	16.67 (8.33–38.83) N=503
65 to 69	115/863 13.33%	297/869 34.18%	199/869 22.90%	410/857 47.84%	16.67 (8.33–29.17) N=861
70 to 74	108/802 13.47%	347/800 43.38%	254/803 31.63%	330/778 42.42%	15.33 (4.17–18.75) N=798
Greater than 75	49/389 12.60%	174/391 44.50%	117/391 29.92%	121/372 32.53%	16.67 (8.33–16.67) N=380
Total	351/2928 11.99%	1,081/2,940 36.77%	757/2,943 25.72%	1,316/2,873 45.81%	16.67 (5.5–27.83) N=2,910



**Movember Team**  
PO BOX 60  
East Melbourne  
VICTORIA 8002  
Australia

---

**1300 GROW MO**  
(1300 4769 66)

**www.movember.com**  
info@movember.com

Editorial assistance for the  
PCOR-ANZ Annual Report 2024  
was provided by Lesley Cunliffe  
(PhD) and funded by Movember.



All rights reserved. Distribution or circulation of this publication (including photocopying or storing it in any medium by electronic means) may be done without the written permission of the copyright owner, provided that the source is fully acknowledged and no modification(s) or amendment(s) is made. Any amendment, modification or change to this publication (whether accidental or intentional) must only be done with the prior written permission of the copyright owner. All applications must be addressed to the publisher.  
© 2025 Movember Group Pty Ltd as Trustee for the Movember Foundation (ABN 48 894 537 905). Published September 2025 by Movember.